Bruce H. Davis, M.D.

Founder and President of Trillium Diagnostics, is a Hematopathologist, who received his education at Cornell University (B.S.) and University of Connecticut (M.D.).  He started his academic career at Upstate-SUNY Medical Center in Syracuse, NY where he developed his interest in flow cytometry as a diagnostic tool in medicine.  He then moved to Dartmouth-Hitchcock Medical Center, where he published extensively on reticulocyte analysis by flow cytometry and developed the diagnostic concept of the immature reticulocyte fraction, which is now a standard diagnostic parameter in anemia assessment in laboratory hematology.  His research at Dartmouth also included the diagnostic utility of neutrophil CD64 for infection and sepsis.  Dr. Davis co-founded with the late Dr. Berend Houwen from Groningen. NL the International Society for Laboratory Hematology and the journal Laboratory Hematology.  Dr. Davis was Director of Flow Cytometry at William Beaumont Hospital in Michigan during 1994 – 2000; there he developed the first FDA-cleared method for fetomaternal hemorrhage detection using a flow cytometric technique with anti-HbF monoclonal antibodies.  He has been active in numerous professional organizations and societies, having served as President for the Clinical Cytometry Society, Treasurer and Board member for the International Society for Laboratory Hematology, member of the Hematology Resource Committee for the College of American Pathologists, Treasurer for the International Committee for the Standardization of Haematology, and Chair of the area committee on hematology for CLSI (formerly NCCLS).  He has over 100 peer-reviewed publications and serves on the editorial boards for journals of cytometry and laboratory hematology and has provided consultation to a number of medical diagnostic companies.  Dr. Davis returned to his native New England at the turn of the century to establish Trillium Diagnostic, LLC, from which he continues his consulting activities, research and development of new diagnostic products for laboratory hematology, and works to establish acceptance of Leuko64 as a superior diagnostic assay for the detection of infection and sepsis.